Advances in the amplification of HER2 in metastatic colorectal cancer
10.3760/cma.j.cn371439-20200715-00049
- VernacularTitle:HER2扩增在转移性结直肠癌中的研究进展
- Author:
Jiaojiao YU
1
;
Jun WANG
;
Likang WANG
;
Nan YAO
Author Information
1. 兰州大学第一临床医学院 730000
- Keywords:
Colorectal neoplasms;
Genes, erbB-2;
Biomarkers;
Molecular targeted therapy
- From:
Journal of International Oncology
2021;48(4):246-249
- CountryChina
- Language:Chinese
-
Abstract:
Several studies have shown that human epidermal growth factor receptor 2 (HER2) amplification could be a predictive biomarker of resistance to anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS wild-type metastatic colorectal cancer (mCRC). Dual HER2 inhibition with trastuzumab plus lapatinib or pertuzumab has shown promising preliminary anti-tumoral efficacy in RAS wild-type mCRC. HER2-targeted therapeutic strategies have the potential to change the treatment paradigm for a clinically relevant subgroup of patients with mCRC.
